Creaney J, Yeoman D, et al.
Journal of Thoracic Oncology. 2008;3(8):851-857.
Researchers investigated three biomarkers recently identified in mesothelioma to assess the accuracy of each marker in the same sample population and to assess if the accuracy could be improved with the combination of markers. 167 patients were enrolled in the study, 66 patients diagnosed with mesothelioma, 20 healthy patients, 21 patients with benign asbestos related disease, 30 patients with non-malignant pleural effusions, and 30 patients with lung cancer or another malignancy (breast cancer, colon cancer, etc.).
As has previously been reported by the author, serum mesothelin (MESOMARK) values were elevated in mesothelioma patients compared to healthy controls and other benign conditions. Osteopontin levels were elevated in patients with mesothelioma; however they were also elevated in other malignancies.
MPF was elevated in mesothelioma patients; no difference was seen in levels between patients with mesothelioma, lung cancer or patients with other malignant effusions. Mesothelin showed the highest AUC in the ROC at 0.915 compared to osteopontin and MPF, 0.757 and 0.614 respectively. Only one individual in this cohort had elevated MPF and osteopontin with a negative mesothelin result. The markers when combined together did not improve the sensitivity and specificity compared to mesothelin alone. Creaney et al conclude that the combination of markers do not add to the sensitivity and that mesothelin represents the best biomarker available for mesothelioma.